Our survival analysis found that high miR-20b expression and TP53 mutation are independent risk factors in AML patients received chemotherapy only, but the other widely-used genetic characteristics, such as FLT3-ITD and NPM1 and DNMT3A mutations, are not associated with EFS and OS. This evidence concerns the gene FLT3 and acute myeloid leukemia.